CTSO - Cytosorbents Corporation
| Previous Close | 11.00 |
| Open | 10.80 |
| Bid | 10.90 x 900 |
| Ask | 10.90 x 1000 |
| Day's Range | 10.10 - 11.02 |
| 52 Week Range | 4.00 - 12.35 |
| Volume | 340,414 |
| Avg. Volume | 311,363 |
| Market Cap | 324.467M |
| Beta | 1.40 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.36 |
| Earnings Date | Aug 6, 2018 - Aug 10, 2018 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 12.75 |
- PR Newswire•13 days ago
CytoSorbents Officially Opens New U.S. CytoSorb Manufacturing Facility
MONMOUTH JUNCTION, N.J., June 12, 2018 /PRNewswire/ -- CytoSorbents Corporation (CTSO), a critical care immunotherapy leader using its CytoSorb® blood purification technology to treat deadly inflammation in critically-ill and cardiac surgery patients around the world, announced receipt of regulatory approval to begin production of CytoSorb in its new manufacturing facility in Monmouth Junction, New Jersey, under the Company's ISO 13485:2003 certificate.
- PR Newswire•21 days ago
CytoSorbents to Present at the Jefferies 2018 Global Healthcare Conference
MONMOUTH JUNCTION, N.J. , June 4, 2018 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunotherapy leader using its CytoSorb® blood purification technology to treat deadly inflammation ...
- PR Newswire•last month
CytoSorbents to Present at the 19th Annual B. Riley FBR Investor Conference
MONMOUTH JUNCTION, N.J. , May 21, 2018 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunotherapy leader using its CytoSorb® blood purification technology to treat deadly inflammation ...
- PR Newswire•last month
CytoSorb® Adds Bilirubin and Myoglobin Reduction to European Union Approved Indications for Use
Broadened indications expand the role of CytoSorb in treating liver disease and trauma MONMOUTH JUNCTION, N.J. , May 14, 2018 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunotherapy ...
- Zacks Small Cap Research•2 months ago
CTSO: Q1 2018 Update: Product Sales New Record. REFRESH 2 Enrollment Should Pick Up Steam. REMOVE Already Ramping
Product sales, while a hair below our estimate, continue to climb with Q1 marking the 11th consecutive quarter of setting a new high. Product sales growth is broad based – with both direct (i.e. CTSO is guiding for product sales to increase sequentially (i.e.
- Associated Press•2 months ago
CytoSorbents: 1Q Earnings Snapshot
The Monmouth Junction, New Jersey-based company said it had a loss of 10 cents per share. The results beat Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment ...
- PR Newswire•2 months ago
CytoSorbents Reports Strong First Quarter 2018 Financial Results
MONMOUTH JUNCTION, N.J. , May 8, 2018 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunotherapy leader using its CytoSorb® blood purification technology to treat deadly inflammation ...
- Simply Wall St.•2 months ago
What You Must Know About Cytosorbents Corporation’s (NASDAQ:CTSO) Financial Strength
Investors are always looking for growth in small-cap stocks like Cytosorbents Corporation (NASDAQ:CTSO), with a market cap of US$242.86M. However, an important fact which most ignore is: how financially healthyRead More...
- GlobeNewswire•2 months ago
New Research: Key Drivers of Growth for Lincoln Electric, Cytosorbents, Materion, Fortune Brands Home & Security, Washington Real Estate Investment Trust, and CPB — Factors of Influence, Major Initiatives and Sustained Production
NEW YORK, May 04, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Lincoln ...
- PR Newswire•2 months ago
CytoSorbents to Report Q1 2018 Operating and Financial Results
MONMOUTH JUNCTION, N.J. , May 2, 2018 /PRNewswire/ -- CytoSorbents Corporation (CTSO), CytoSorbents Corporation (CTSO), a critical care immunotherapy leader commercializing its CytoSorb® blood purification ...
- PR Newswire•2 months ago
CytoSorbents Enrolls First Patient into Pivotal U.S. REFRESH 2-AKI Trial Using CytoSorb® During Complex Cardiac Surgery
MONMOUTH JUNCTION, N.J. , April 24, 2018 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunotherapy leader using its CytoSorb® blood purification technology to treat deadly ...
- PR Newswire•3 months ago
CytoSorbents to Meet With European Investors at the H.C. Wainwright Annual Global Life Sciences Conference in Monte Carlo and in Meetings in Frankfurt, Geneva and Zurich
MONMOUTH JUNCTION, N.J. , April 9, 2018 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunotherapy leader using its CytoSorb® blood purification technology to treat deadly ...
- PR Newswire•3 months ago
CytoSorbents Refinances Existing Debt with New $15 Million Debt Facility with Bridge Bank
MONMOUTH JUNCTION, N.J., April 4, 2018 /PRNewswire/ -- CytoSorbents Corporation (CTSO), a critical care immunotherapy leader using CytoSorb® blood purification to treat deadly inflammation in critically-ill and cardiac surgery patients around the world, announced that it has refinanced its existing $10 million term loan with a new $15 million debt facility with Bridge Bank. On March 29, 2018, CytoSorbents entered into an Amended and Restated Loan and Security Agreement with Bridge Bank, which replaced its existing $10 million term loan with $10 million of new debt. This new debt facility is structured as a 4-year term loan, with monthly payments of interest-only for the first 18 months, followed by monthly payments of principal and interest through the remainder of the term. No change was made to the success fee terms of the first loan.
- PR Newswire•3 months ago
CytoSorbents Reports on the Successful 5th International CytoSorb Users Meeting and 38th ISICEM Critical Care Conference
MONMOUTH JUNCTION, N.J., March 28, 2018 /PRNewswire/ -- CytoSorbents Corporation (CTSO), a critical care immunotherapy leader using blood purification to treat deadly inflammation in critically-ill and cardiac surgery patients around the world, reports on the success of its 5th International CytoSorb Users Meeting and a record turnout during its Satellite Research Symposium at the 38th International Symposium of Intensive Care and Emergency Medicine (ISICEM) in Brussels, Belgium last week. ISICEM is one the largest and most influential critical care conferences in the world which takes place in Brussels, Belgium every spring. The conference was very well-attended, with approximately 6,200 participants this year, and an impressive speaker list of hundreds of leading international key opinion leaders (KOL) in intensive care and emergency medicine.
- Zacks Small Cap Research•3 months ago
CTSO: Q4 2017 Update: Q4 / FY Product Sales +64% / 63%, Product Margin Jumps 900bp. FDA Pivotal Study Underway
CytoSorbents (CTSO) reported financial results for their fourth quarter ending December 31st and provided a business update. Product sales continue their regular and rapid climb upward, setting another record and besting the prior high (Q3 2017) by almost 25%. Product sales were also ahead of our (pre pre-announcement) estimate by more than 27%. Q4 also marked the third consecutive quarter that product sale reached a new peak, following a slight (
- PR Newswire•3 months ago
CytoSorbents to Present at the 38th Annual Cowen Healthcare Conference
MONMOUTH JUNCTION, N.J. , March 12, 2018 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunotherapy leader using blood purification to treat deadly inflammation in critically-ill ...
- PR Newswire•4 months ago
CytoSorbents Achieves Record Revenue and Product Sales Growth in 2017
MONMOUTH JUNCTION, N.J. , March 8, 2018 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunotherapy leader using CytoSorb® blood purification to treat deadly inflammation in ...
- ACCESSWIRE•4 months ago
CytoSorbents Corporation to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / March 8, 2018 / CytoSorbents Corporation (NASDAQ: CTSO ) will be discussing their earnings results in their Q4 Earnings Call to be held on March 8, 2018, at 4:45 PM Eastern ...
- PR Newswire•4 months ago
CytoSorbents to Report Fiscal 2017 Operating and Financial Results
MONMOUTH JUNCTION, N.J. , March 1, 2018 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunotherapy leader using blood purification to treat deadly inflammation in critically-ill ...
- PR Newswire•4 months ago
CytoSorbents to Participate at the BTIG Healthcare Conference
MONMOUTH JUNCTION, N.J. , Feb. 26, 2018 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunotherapy leader using blood purification to treat deadly inflammation in critically-ill ...
- PR Newswire•4 months ago
CytoSorbents Expands Its Partnership with Biocon to Launch CytoSorb® in Malaysia
Expands upon Biocon's successful commercialization of CytoSorb in India and leverages its substantial commitment to the Malaysian market MONMOUTH JUNCTION, N.J. , Feb. 15, 2018 /PRNewswire/ -- CytoSorbents ...
- PR Newswire•5 months ago
CytoSorbents to Present at the 20th Annual BIO CEO & Investor Conference
MONMOUTH JUNCTION, N.J., Feb. 6, 2018 /PRNewswire/ -- CytoSorbents Corporation (CTSO), a critical care immunotherapy leader using blood purification to treat deadly inflammation in critically-ill and cardiac surgery patients around the world, announced that its Chief Executive Officer, Dr. Phillip Chan, MD, PhD, will present at the 20th Annual BIO CEO & Investor Conference next week in New York City.
- PR Newswire•5 months ago
New Study Demonstrates Improved Hemodynamic Stability After Heart Transplant Surgery using Intraoperative CytoSorb® Blood Purification
MONMOUTH JUNCTION, N.J. , Feb. 1, 2018 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunotherapy leader commercializing its CytoSorb® blood purification technology to treat ...
Yahoo Finance Video•4 months agoCytoSorbents' CEO on flu epidemic
The Center for Disease Control estimates that the most prominent strain could leave as many as fifty thousand Americans dead by the end of this year's flu season. Here to discuss this year's flu season and what hospitals can do to address this epidemic is Phil Chan CEO of CytoSorbents.
